 |
Tina W. F. Yen, MD, MS
Assistant Professor, Surgery
|
Dr. Yen is a surgical oncologist with clinical and research interests in breast cancer, endocrine tumors, and health services. She has studied multiple aspects of care related to the management of ductal carcinoma in situ of the breast and outcomes of patients who undergo surgery for medullary thyroid carcinoma and primary hyperparathyroidism. Her present research focuses on studying breast cancer quality of care, patterns of care, and the relationship of these patterns of care to outcomes of care through the analysis of administrative data, Medicare claims, and tumor registry data. Current projects include studying lymphedema incidence and risk factors among older breast cancer women (funded by a Career Development Award by the National Institutes of Health) and hormone therapy use in older breast cancer women.
Representative Publications
Yen TW, Sandgren EP, Liggitt HD, Palmiter RD, Zhou W, Hinds TR, Grippo PJ, McDonald JM, Robinson LM, Bell RH. The gastrin receptor promotes pancreatic growth in transgenic mice. Pancreas 2002;24:121-9.
Yen TW, Aardal NP, Bronner MB, Thorning DR, Savard CE, Lee,RH, Bell RH. Myofibroblasts are responsible for the desmoplastic reaction surrounding human pancreatic carcinomas. Surgery 2002;131:129-34.
Yen TW, Mann GN, Lawton TJ, Livingston RB, Anderson BO. An axillary recurrence of breast cancer following a negative sentinel lymph node biopsy. Breast J 2003;9:234-6.
Chagpar A, Yen TW, Sahin A, Hunt KK, Whitman GJ, Ames FC, Ross MI, Meric-Bernstam F, Babiera GV, Singletary SE, Kuerer HM.Intraoperative margin assessment reduces re-excision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg 2003;186:371-7.
Yen TW, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB. Medullary thyroid carcinoma: Results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 2003;134:890-901.
Yen TW, Hunt KK, Mirza NQ, Thomas ES, Singletary SE, Babiera GV, Meric-Bernstam F, Buchholz TA, Feig BW, Ross MI, Ames FC, Theriault RL, Kuerer HM. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen following surgery for ductal carcinoma in situ. Cancer 2004;100:942-9.
Yen TW, Hunt KK, Ross MI, Mirza NQ, Babiera GV, Meric-Bernstam F, Singletary SE, Symmans WF, Giordano SH. Feig BW, Ames FC, Kuerer HM. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: A guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg 2005;200:516-26.
Yen TW, Wilson SD, Krzywda EA, Sugg SL. The role of parathyroid hormone (PTH) measurements after surgery for primary hyperparathyroidism. Surgery 2006;140:665-74.
Yen TW, Kuerer HM, Ottesen RA, Rouse L, Niland JC, Edge SB, Theriault RL, Weeks JC. Impact of randomized clinical trial results on the use of tamoxifen following breast surgery for ductal carcinoma in situ in the National Comprehensive Cancer Network. J Clin Oncol 2007;25:3251-3258.